Your browser doesn't support javascript.
loading
Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control.
Lillegraven, Siri; Paulshus Sundlisæter, Nina; Aga, Anna-Birgitte; Sexton, Joseph; Solomon, Daniel H; van der Heijde, Désirée; Haavardsholm, Espen A.
Afiliação
  • Lillegraven S; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
  • Paulshus Sundlisæter N; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
  • Aga AB; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
  • Sexton J; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
  • Solomon DH; Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts.
  • van der Heijde D; Leiden University Medical Centre, Department of Rheumatology, Leiden, the Netherlands.
  • Haavardsholm EA; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
JAMA ; 329(12): 1024-1026, 2023 03 28.
Article em En | MEDLINE | ID: mdl-36976288
This open-label randomized clinical trial assessed the 12-month risk of disease activity flares after discontinuation of conventional synthetic DMARDs (csDMARDs) compared with continuing half-dose csDMARDs in adult Norwegian patients with rheumatoid arthritis and excellent disease control.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos / Suspensão de Tratamento Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos / Suspensão de Tratamento Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article